2021
Co-inhibitor expression on tumor infiltrating and splenic lymphocytes after dual checkpoint inhibition in a microsatellite stable model of colorectal cancer
Slovak RJ, Park HJ, Kamp WM, Ludwig JM, Kang I, Kim HS. Co-inhibitor expression on tumor infiltrating and splenic lymphocytes after dual checkpoint inhibition in a microsatellite stable model of colorectal cancer. Scientific Reports 2021, 11: 6956. PMID: 33772035, PMCID: PMC7997991, DOI: 10.1038/s41598-021-85810-5.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntigens, CDCD4-Positive T-LymphocytesCell Line, TumorCell ProliferationColorectal NeoplasmsCTLA-4 AntigenFemaleHepatitis A Virus Cellular Receptor 2Immune Checkpoint InhibitorsLymphocyte Activation Gene 3 ProteinLymphocytes, Tumor-InfiltratingMaleMiceMice, Inbred BALB CMicrosatellite RepeatsProgrammed Cell Death 1 ReceptorSpleenT-Lymphocytes, CytotoxicConceptsDual checkpoint inhibitionPD-1 inhibitionColorectal cancerCheckpoint inhibitionPD-1Checkpoint inhibitorsT cellsImmune responseRobust anti-tumor immune responseAnti-PD-1 groupAnti-PD-1 antibodyAnti-tumor immune responseMicrosatellite stable colorectal cancerDual PD-1Majority of patientsDeficient mismatch repairStable colorectal cancerCTLA-4 inhibitionTumor growth rateHigh microsatellite instabilityPotential escape mechanismsCombination immunotherapyImmunosuppressive checkpointsTumoral infiltrationDual therapy
2020
Quantification of immune response after dual checkpoint inhibition in a microsatellite stable model of colorectal cancer.
Kamp W, Park H, Slovak R, Ludwig J, Kang I, Kim H. Quantification of immune response after dual checkpoint inhibition in a microsatellite stable model of colorectal cancer. Journal Of Clinical Oncology 2020, 38: 160-160. DOI: 10.1200/jco.2020.38.4_suppl.160.Peer-Reviewed Original ResearchDual immune checkpoint blockadeAnti-PD-1 antibodyColorectal cancerPD-1T cellsImmune responseMurine colorectal cancer cellsBALB/c miceDual checkpoint inhibitionExpression of TIM3Subcutaneous flank injectionNumber of CD8PD-1 inhibitionImmune checkpoint blockadeDeficient mismatch repairColorectal cancer cellsHigh microsatellite instabilitySignificant clinical impactPotential escape mechanismsCombination immunotherapyImmunosuppressive checkpointsCheckpoint inhibitorsMonotherapy groupCheckpoint blockadeMost patients
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply